{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"MAGNETISMM-32","nct_id":"NCT06152575","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=magnetismm-32-nct06152575. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive elranatamab monotherapy","label":"Elranatamab","type":"EXPERIMENTAL"},{"description":"Participants will receive either Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd)","label":"Investigator's Choice","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-12-30","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":492,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Elranatamab","otherNames":[],"type":"DRUG"},{"name":"Elotuzumab","otherNames":[],"type":"DRUG"},{"name":"Pomalidomide","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Bortezomib","otherNames":[],"type":"DRUG"},{"name":"Carfilzomib","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-24","lead_sponsor":"Pfizer","official_title":"A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-08-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival per International Myeloma Working Group criteria","timeFrame":"Up to approximately 5 years"}],"references":[],"start_date":{"date":"2024-02-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","url":"https://clinicaltrials.gov/study/NCT06152575"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/magnetismm-32-nct06152575"}